Protein 4.1 R Suppresses Melanoma Progression by Inhibiting Glycolysis via the PI3K/AKT/mTOR Pathway
Molecular Carcinogenesis · 2026-12 · 65 (12) · 1582-1595
DOI: 10.1002/mc.70179 ↗At a glance
Journal article in Molecular Carcinogenesis, published online on 2026-09-19. Written by Kai Yang and 11 co-authors. Institution: Henan Institute of Medical and Pharmaceutical Sciences, Academy of Medical Science, Zhengzhou University, Zhengzhou, China. Major MEDLINE topics: TOR Serine-Threonine Kinases, Glycolysis, Proto-Oncogene Proteins c-akt, Phosphatidylinositol 3-Kinases. 43 references. Funded by: the Project of Basic Research Fund of Henan Institute of Medical and Pharmacological Sciences.
Abstract (original language)
Melanoma is a highly aggressive malignancy with strong metastatic potential. Protein 4.1 R, encoded by EPB41 , is a membrane cytoskeleton protein that plays an essential role in maintaining plasma membrane stability and cytoskeletal organization. Recent studies have indicated that the protein 4.1 R played a tumor‐suppressive role in multiple cancer types. However, the relationship between protein 4.1 R and glycolysis in melanoma remains unclear. In this study, we aimed to explore the relationship between protein 4.1 R expression and glucose metabolism and its mechanism of action in melanoma. Our results indicated that protein 4.1 R silencing significantly promoted the proliferation, migration and invasion of melanoma cells in vitro and accelerated tumor growth in vivo and increased glucose consumption, extracellular acidification rate, and lactate and ATP production, accompanied by reduced oxidative phosphorylation (OXPHOS). Protein 4.1 R silencing was associated with increased phosphorylation of PI3K, AKT and mTOR signaling components. Treatment with the PI3K inhibitor LY294002 partially reversed the effects of protein 4.1 R knockdown on melanoma cells. In conclusion, these findings suggest that protein 4.1 R may negatively regulate melanoma progression through mechanisms associated with glycolytic remodeling and PI3K/AKT/mTOR signaling.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Henan Institute of Medical and Pharmaceutical Sciences, Academy of Medical Science, Zhengzhou University, Zhengzhou, China.
- Institute of Children's Health, Henan Academy of Medical Sciences, Zhengzhou, China.
- The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, P.R. China.
- Department of Pathology, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, P.R. China.
ORCID profiles: Shuangshuang Guo, Zhenyu Ji
Funding
- the Project of Basic Research Fund of Henan Institute of Medical and Pharmacological Sciences
Cite
APA
Yang, K., Gao, X., Sun, C., Zhao, L., Zhang, Y., Zhang, Y., Yang, Y., Guo, S., Chen, M., Li, H., Ji, Z., & Fan, D. (2026). Protein 4.1 R Suppresses Melanoma Progression by Inhibiting Glycolysis via the PI3K/AKT/mTOR Pathway. Molecular Carcinogenesis, 65(12), 1582-1595. https://doi.org/10.1002/mc.70179
Vancouver
Yang K, Gao X, Sun C, Zhao L, Zhang Y, Zhang Y, et al. Protein 4.1 R Suppresses Melanoma Progression by Inhibiting Glycolysis via the PI3K/AKT/mTOR Pathway. Molecular Carcinogenesis. 2026;65(12):1582-1595. doi:10.1002/mc.70179
BibTeX
@article{Yang2026,
author = {Yang, Kai and Gao, Xian and Sun, Chuanxi and Zhao, Luyang and Zhang, Yuanyuan and Zhang, Yujie and Yang, Yuhao and Guo, Shuangshuang and Chen, Miaomiao and Li, Hanhan and Ji, Zhenyu and Fan, Dandan},
title = {Protein 4.1 R Suppresses Melanoma Progression by Inhibiting Glycolysis via the PI3K/AKT/mTOR Pathway},
journal = {Molecular Carcinogenesis},
year = {2026},
volume = {65},
number = {12},
pages = {1582--1595},
doi = {10.1002/mc.70179}
}
EUVIMED